This view is further supported by our finding that the 3‐microRNA signature measured in blood from MCI patients and controls is performing similar to the CSF analysis of the Aβ42/40 ratio—an established AD biomarker—at a time point when phospho‐tau levels are still similar among groups. The gene discussed is MAPT; the disease is Alzheimer disease.